Onxeo Appoints Dr. Shefali Agarwal as Chief Executive Officer

>> >> Dr. Agarwal has been Chairman of the Onxeo Board of Directors since June 2021.

>> >> The company presents the first element of its development strategy. This includes preparing for a pre-IND meeting for AsiDNA®, the first-in-class tumor DNA damage response inhibitor, and implementing infrastructure in the United States.

>> >> New funding extends Onxeo’s financial visibility to 2.th 2023 quarter

Paris – (Business Wire) – Regulatory News:

Onxeo SA (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), Onxeo ” where ” society A clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA damage response (DDR) mechanisms to combat rare or resistant cancers today leads Dr. Shefali Agarwal. Announced that he has been appointed as the person in charge. Dr. Agarwal replaces Julien Miara, Director of Invus SAS, who was appointed Interim CEO in January 2022.

“I have worked closely with Dr. Agarwal as Chairman of the Board to grow the company, strengthen the Board and, most importantly, advance the product portfolio. It has become very clear to me and the Board that Dr. Agarwal is the right choice to play the role of Chief Executive Officer. “ Said Julian Miara, Acting General Manager.. “She works with an experienced team to quickly deploy AsiDNA® to the clinic, expand her preclinical product portfolio, and consider visibility in the US investment community for international visibility to Onxeo. We have the expertise to provide sex. »»

Dr. Agarwal is a trained physician and, until recently, Chief Medical and Development Officer at Epizyme, Inc., a biopharmacy company developing new epigenetic therapies for cancer, with global clinical development and regulatory strategies. I was leading. She will continue to be an Epizyme advisor while performing her duties at Onxeo.

“We are honored to be Chief Executive Officer of Onxeo. We look forward to working more closely with this talented team to continue to grow our business. We have extensive experience in oncology. Thinking about it, I’m encouraged by the work done at Onxeo and the opportunities created by the platON® platform. “ and Dr. Shefali Agarwal said.. “We will continue to introduce AsiDNA®, the first tumor DNA damage response inhibitor in its class, to the clinic and conduct preclinical proof-of-concept studies using the new PARP agonist generation OX401 and its enhanced version. Looking for ways to achieve clinical outcomes in the United States, refocusing on clinical research efforts in the United States, developing infrastructure in the United States, and expanding teams at Massachusetts, a rapidly expanding biotechnology hub. We are pleased to say that the new funding from two major shareholders who support our vision expands our financial visibility through the second quarter of 2023 and achieves our goals. Helps to do. “

Prior to joining Epizyme in 2018, Dr. Agarwal held various leadership positions in medical research, clinical development and operations, and medical issues. She was Chief Medical Officer at SQZ Biotech, building and leading a clinical development organization that includes clinical research operations and regulatory functions. Prior to SQZ Biotech, she was a leader in Curis and Tesaro. She oversaw Phase 2 trials of dual HDAC / PI3K inhibitors in her diffuse large B-cell lymphoma and Phase 1 trials of oral checkpoint inhibitors in solid tumors. At Tesaro, she led the US and European marketing applications for ZEJULA® (niraparib) in ovarian cancer. Shefali has also held senior positions at Covidien, AVEO Oncology and Pfizer.

In addition to his degree in medicine, Dr. Agarwal holds a master’s degree in public health and a master’s degree in business science. Dr. Agarwal is a member of the board of directors of three US biotechnology companies: ITB Med (unlisted), Gritstone Bio (NASDAQ: GRTS), and Fate Therapeutics (Nasdaq: FATE). She is also a member of Imvax, Inc.’s Scientific Advisory Board and the founder of the Cancer Shakti Foundation, a voluntary non-profit foundation aimed at raising awareness of cancer issues.

Dr. Robert L. Coleman, Onxeo Board Member and Science Director of American Oncology Research Said : “We are pleased to welcome Dr. Agarwal to Onxeo as Chief Executive Officer. She has unique expertise and clinical insights in Onxeo based on her successful career in management at several biopharmacy companies. This experience provides him with a clear vision of unmet clinical needs, treatment environment, regulatory processes, and financial management, which help to succeed in drug development strategies and business growth. Helps. It is a great honor for me to work with him to bring therapeutic active ingredients to the clinic based on a very original mechanism of action. On behalf of Onxeo’s board of directors, Dr. Agarwal We welcome the role of new leadership »».

About Onxeo

Onxeo (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO) is a new anti-cancer by targeting tumor DNA function through an unparalleled mechanism of action in the highly sought after DNA damage response (DDR) field. A clinical biotechnology company that develops cancer drugs. We focus on developing innovative first-in-class or disruptive compounds (internal, acquisition, or licensing) from translational research to human proof-of-concept, a turning point that creates value. Attractive for potential partners.

Plato Is Onxeo’s decoy oligonucleotide chemistry platform, committed to the creation of new and innovative compounds aimed at expanding our product portfolio.

AsiDNA, Plato’s lead compounds are highly differentiated first-in-call clinical stage candidates in the field of DNA damage response (DDR) applied in oncology. Its decoy and agonist mechanisms, which act upstream of multiple DDR pathways, are capable of preventing or abolishing tumor resistance to targeted therapies such as PARP inhibitors, and are potent with damaging agent tumor DNA such as radiation / chemotherapy. It brings unique antitumor properties such as synergistic effects. AsiDNA is currently in clinical trials combining difficult-to-treat solid tumors.

OX401 Is a new candidate produced by platON, designed as a potent PARP agonist, which acts on both DNA damage response and immune response activation without inducing resistance. OX401 is in the optimization and preclinical proof-of-concept stage, alone or in combination with immunotherapy.

For more information, please visit www.onxeo.com.

Description of future prospects

This press release contains, implicitly or explicitly, statements about specific future prospects related to Onxeo and its business. These statements depend on certain known or unknown risks, uncertainties, and other factors. These factors can cause Onxeo’s actual results, financial condition, performance, or outcomes to differ materially from those expressed or implied by such. A description of the future outlook. Onxeo has issued this press release as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events, etc. Risk factors described in the latest document for an explanation of the risks and uncertainties that Onxeo’s actual results, financial position, performance or performance may differ from those contained in the forward-looking statements. Or see Others. Regular financial reports or press releases available free of charge on our website (www.onxeo.com) and / or AMF (www.amf-france.org).

contact address

Valerie Leroy

[email protected]
+33 1 45 58 76 00

Public Relations-France
Nicholas Merigot


[email protected]
+33 1 44 71 94 98

Public Relations-US
Aulani Putin, Real Chemistry

[email protected]
+1 559 355 2673

Investor Public Relations / Strategic Communication
Dušan Orešan ský / Emmanuel Yuin


[email protected]
+33 1 44 71 94 92 92